Forty years after the first totally implantable venous access device (TIVAD) implant: the pure surgical cut-down technique only avoids immediate complications that can be fatal.
Percutaneous approach
Pneumothorax
Port-a-cath
Surgical cut-down
Totally implantable venous access device (TIVAD)
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
18
05
2021
accepted:
01
06
2021
pubmed:
11
6
2021
medline:
2
10
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
Even though TIVADs have been implanted for a long time, immediate complications are still occurring. The aim of this work was to review different techniques of placing TIVAD implants to evaluate the aetiology of immediate complications. A systematic literature review was performed using the PubMed, Cochrane and Google Scholar databases in accordance with the PRISMA guidelines. The patient numbers, number of implanted devices, specialists involved, implant techniques, implant sites and immediate complication onsets were studied. Of the 1256 manuscripts reviewed, 36 were eligible for inclusion in the study, for a total of 17,388 patients with equivalent TIVAD implantation. A total of 2745 patients (15.8%) were treated with a surgical technique and 14,643 patients (84.2%) were treated with a percutaneous technique. Of the 2745 devices (15.8%) implanted by a surgical technique, 1721 devices (62.7%) were placed in the cephalic vein (CFV). Of the 14,643 implants (84.2%) placed with a percutaneous technique, 5784 devices (39.5%) were placed in the internal jugular vein (IJV), and 5321 devices (36.3%) were placed in the subclavian vein (SCV). The number of immediate complications in patients undergoing surgical techniques was 32 (1.2%) HMMs. In patients treated with a percutaneous technique, the number of total complications were 333 (2.8%): 71 PNX (0.5%), 2 HMT (0.01%), 175 accidental artery punctures AAP (1.2%) and 85 HMM (0.6%). No mortality was reported with either technique. The percutaneous approach is currently the most commonly used technique to implant a TIVAD, but despite specialist's best efforts, immediate complications are still occurring. Surgical cut-down, 40 years after the first implant, is still the only technique that can avoid all of the immediate complications that can be fatal.
Identifiants
pubmed: 34109472
doi: 10.1007/s00423-021-02225-6
pii: 10.1007/s00423-021-02225-6
pmc: PMC8481188
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1739-1749Informations de copyright
© 2021. The Author(s).
Références
Ann Surg Oncol. 2005 Jul;12(7):570-3
pubmed: 15889215
J Vasc Access. 2016 Nov 2;17(6):527-534
pubmed: 27768211
Ann Coloproctol. 2015 Apr;31(2):63-7
pubmed: 25960974
Ann Surg. 2011 Jun;253(6):1111-7
pubmed: 21412146
Eur J Surg Oncol. 2011 Oct;37(10):913-8
pubmed: 21831566
PLoS One. 2020 Nov 24;15(11):e0242727
pubmed: 33232361
Langenbecks Arch Surg. 2021 May;406(3):903-910
pubmed: 33550438
Acad Radiol. 2010 Apr;17(4):464-7
pubmed: 20060749
Surg Innov. 2013 Dec;20(6):566-9
pubmed: 23445713
World J Surg. 2017 May;41(5):1398
pubmed: 27896405
Indian J Surg Oncol. 2020 Sep;11(3):418-422
pubmed: 33013121
Br J Surg. 2009 Feb;96(2):159-65
pubmed: 19160366
Geriatr Gerontol Int. 2019 Mar;19(3):218-221
pubmed: 30724007
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
BMC Surg. 2019 Dec 11;19(1):189
pubmed: 31829196
Surg Today. 2013 Jul;43(7):745-50
pubmed: 22922950
Ann Surg Oncol. 2015;22(6):1943-9
pubmed: 25404473
J Chin Med Assoc. 2014 May;77(5):246-52
pubmed: 24726676
J Vasc Access. 2019 Mar;20(2):134-139
pubmed: 29923460
Acta Anaesthesiol Scand. 2020 Mar;64(3):385-393
pubmed: 31721153
In Vivo. 2019 Nov-Dec;33(6):2079-2085
pubmed: 31662541
Turk Gogus Kalp Damar Cerrahisi Derg. 2019 Oct 23;27(4):499-507
pubmed: 32082916
J BUON. 2015 Jan-Feb;20(1):338-45
pubmed: 25778336
J Surg Oncol. 2015 Jul;112(1):56-9
pubmed: 26175279
Int Surg. 2014 Jul-Aug;99(4):475-8
pubmed: 25058787
Ann Surg Oncol. 2010 Jun;17(6):1649-56
pubmed: 20204533
Ann Med Surg (Lond). 2017 Jul 25;21:81-84
pubmed: 28794870
Am J Clin Oncol. 2017 Feb;40(1):94-105
pubmed: 28106685
Ann Vasc Surg. 2011 Feb;25(2):217-21
pubmed: 20926248
J Surg Oncol. 2016 Jan;113(1):114-9
pubmed: 26645575
World J Surg Oncol. 2014 Dec 08;12:378
pubmed: 25487539
World J Surg Oncol. 2015 Aug 12;13:243
pubmed: 26264364
J Cancer. 2021 Jan 1;12(5):1379-1385
pubmed: 33531983
J Vasc Access. 2017 Sep 11;18(5):390-395
pubmed: 28731491
Oncol Lett. 2010 Nov;1(6):1029-1031
pubmed: 22870107
Acta radiol. 1953 May;39(5):368-76
pubmed: 13057644
J Vasc Surg Venous Lymphat Disord. 2016 Apr;4(2):200-5
pubmed: 26993868
J Surg Oncol. 2011 Nov 1;104(6):654-6
pubmed: 21671465
J Vasc Interv Radiol. 2014 Sep;25(9):1439-46
pubmed: 24613268
Am Surg. 2014 May;80(5):513-5
pubmed: 24887734
J Surg Oncol. 2017 Mar;115(3):291-295
pubmed: 27813159
Ann Surg. 2020 Dec;272(6):950-960
pubmed: 31800490
Support Care Cancer. 2021 Jul;29(7):3531-3538
pubmed: 33155092
Surg Oncol. 2011 Mar;20(1):20-5
pubmed: 19819688
Med Oncol. 2012 Jun;29(2):1361-4
pubmed: 21380779
Ann Surg Oncol. 2014 Nov;21(12):3725-31
pubmed: 24841352
Arch Surg. 2001 Sep;136(9):1050-3
pubmed: 11529829
J Vasc Access. 2017 Jul 14;18(4):345-351
pubmed: 28665466
Cardiovasc Intervent Radiol. 2004 Jan-Feb;27(1):21-5
pubmed: 15109223
Eur J Surg Oncol. 2019 Feb;45(2):275-278
pubmed: 30087070
Mol Clin Oncol. 2016 Mar;4(3):456-460
pubmed: 26998304
World J Surg Oncol. 2019 Nov 25;17(1):196
pubmed: 31767003
Support Care Cancer. 2013 Feb;21(2):505-10
pubmed: 22829323
Surgery. 1982 Oct;92(4):706-12
pubmed: 7123491
Surgery. 2001 Jun;129(6):768-9
pubmed: 11391380
BMC Surg. 2014 May 08;14:27
pubmed: 24886342